Wissenschaft der HautbarriereArchiv
Reframing Eczema: Th2-Skewed Contact Sensitization, Atopy Patch Testing, and Systemic Contact DermatitisWissenschaft der Hautbarriere 1 min.
We review allergic contact dermatitis (ACD) with predominant Th2 type cytokine expression in the context of chronic cutaneous inflammation. While more has been written about Th1 skewed ACD due to potent allergens in the setting of healthy skin, this review highlights recognition of Th2 skewed ACD in...
Long-Term Dupilumab Treatment Is Not Associated with an Increased Overall Risk of Infections in Adults with Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label 5-Year Extension StudyWissenschaft der Hautbarriere 1 min.
Patients with atopic dermatitis (AD) are at an increased risk for infections. Here, we report a confirmatory follow-up study analyzing the incidence of infections in adults with moderate-to-severe AD treated with dupilumab for up to 5 years. Methods: Infections in adults with moderate-to-severe AD treated...
Development and optimization of Cuscuta reflexa-based hydrogel formulation for management of eczema: in vitro and in vivo approachWissenschaft der Hautbarriere 1 min.
Eczema remains a challenging dermatological condition affecting millions worldwide and current treatments often present limitations and side effects. Dodder or Cuscuta reflexa has documented anti-inflammatory, antioxidant, and antimicrobial properties that may benefit skin conditions. The goal...
Understanding Infantile Atopic Dermatitis: A Review of Environmental, Familial, Genetic and Microbial InfluencesWissenschaft der Hautbarriere 1 min.
This review aims to clarify the early-life risk and protective factors associated with Infantile Atopic Dermatitis (IAD)-an inflammatory skin condition that typically develops between birth and two years of age. The goal was to examine recent findings on maternal, environmental, and microbial influences...
Safety, tolerability, and pharmacokinetics of HL-300, a novel topical pan-JAK inhibitor, in healthy Chinese adults: a first-in-human, randomized, double-blind, placebo-controlled phase I trialWissenschaft der Hautbarriere 1 min.
HL-300 is a novel topical pan-JAK inhibitor targeting JAK1, JAK2, JAK3, and TYK2 for atopic dermatitis (AD). This first-in-human study evaluated its safety, tolerability, and pharmacokinetics (PK) in healthy Chinese adults. In a randomized, double-blind, placebo-controlled phase I trial, 36 subjects...
